International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia

GJ Roboz, T Rosenblat, M Arellano, M Gobbi… - Journal of clinical …, 2014 - ascopubs.org
Purpose Most patients with acute myeloid leukemia (AML) eventually experience relapse.
Relapsed/refractory AML has a dismal prognosis and currently available treatment options …
被引用次数：216 相关文章

International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia

GJ Roboz, T Rosenblat, M Arellano… - Journal of Clinical …, 2014 - scholars.northwestern.edu
Purpose: Most patients with acute myeloid leukemia (AML) eventually experience relapse.
Relapsed/refractory AML has a dismal prognosis and currently available treatment options …

International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia

GJ Roboz, T Rosenblat, M Arellano… - Journal of clinical …, 2014 - pubmed.ncbi.nlm.nih.gov
Purpose Most patients with acute myeloid leukemia (AML) eventually experience relapse.
Relapsed/refractory AML has a dismal prognosis and currently available treatment options …

International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia.

GJ Roboz, T Rosenblat, M Arellano… - Journal of Clinical …, 2014 - europepmc.org
Purpose Most patients with acute myeloid leukemia (AML) eventually experience relapse.
Relapsed/refractory AML has a dismal prognosis and currently available treatment options …

[引用][C] International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia

GJ ROBOZ, T ROSENBLAT, R HILLS… - Journal of clinical …, 2014 - pascal-francis.inist.fr
International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients
With Relapsed/Refractory Acute Myeloid Leukemia CNRS Inist Pascal-Francis CNRS Pascal and …

International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia

GJ Roboz, T Rosenblat, M Arellano, M Gobbi… - Journal of Clinical …, 2014 - cir.nii.ac.jp
< jats: sec>< jats: title> Purpose</jats: title>< jats: p> Most patients with acute myeloid
leukemia (AML) eventually experience relapse. Relapsed/refractory AML has a dismal …
[PDF] researchgate.net

[PDF][PDF] International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia

GJ Roboz, T Rosenblat, M Arellano, M Gobbi… - J Clin …, 2014 - researchgate.net
Purpose Most patients with acute myeloid leukemia (AML) eventually experience relapse.
Relapsed/refractory AML has a dismal prognosis and currently available treatment options …

International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia

GJ Roboz, T Rosenblat, M Arellano… - Journal of Clinical …, 2014 - orca.cardiff.ac.uk
Purpose: Most patients with acute myeloid leukemia (AML) eventually experience relapse.
Relapsed/refractory AML has a dismal prognosis and currently available treatment options …

International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia

GJ Roboz, T Rosenblat, M Arellano… - Journal of Clinical …, 2014 - orca.cardiff.ac.uk
Purpose: Most patients with acute myeloid leukemia (AML) eventually experience relapse.
Relapsed/refractory AML has a dismal prognosis and currently available treatment options …

[引用][C] International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia

GJ ROBOZ, T ROSENBLAT… - Journal of …, 2014 - American Society of Clinical …